Zealand Pharma Informs That Sanofi (France) has Provided an Update on the Commercial Roll-Out of Lyxumia®
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that Sanofi (EURONEXT: SAN and NYSE: SNY) today in its quarterly release for Q2 2013 has provided an update on the commercial roll-out of Lyxumia®. Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist invented by Zealand for the treatment of Type 2 diabetes with world-wide rights to develop and market the product licensed to Sanofi.
Help employers find you! Check out all the jobs and post your resume.
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that Sanofi (EURONEXT: SAN and NYSE: SNY) today in its quarterly release for Q2 2013 has provided an update on the commercial roll-out of Lyxumia®. Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist invented by Zealand for the treatment of Type 2 diabetes with world-wide rights to develop and market the product licensed to Sanofi.
Help employers find you! Check out all the jobs and post your resume.